See more : BankInvest Korte Danske Obligationer (BAIKDOBA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Thyrocare Technologies Limited (THYROCARE.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thyrocare Technologies Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Max Resource Corp. (MXROF) Income Statement Analysis – Financial Results
- PRO CLB GLOBAL LIMITED (PROCLB.BO) Income Statement Analysis – Financial Results
- Bayside Corporation (BYSD) Income Statement Analysis – Financial Results
- China Kepei Education Group Limited (1890.HK) Income Statement Analysis – Financial Results
- Royal Century Resources Holdings Limited (8125.HK) Income Statement Analysis – Financial Results
Thyrocare Technologies Limited (THYROCARE.BO)
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.72B | 5.27B | 5.89B | 4.95B | 4.34B | 4.03B | 3.56B | 3.04B | 2.41B | 1.83B | 1.50B | 1.34B |
| Cost of Revenue | 3.22B | 1.63B | 1.70B | 1.64B | 1.17B | 1.11B | 949.80M | 814.23M | 703.57M | 583.13M | 558.99M | 461.82M |
| Gross Profit | 2.50B | 3.63B | 4.19B | 3.31B | 3.17B | 2.92B | 2.61B | 2.23B | 1.71B | 1.25B | 943.31M | 880.79M |
| Gross Profit Ratio | 43.77% | 69.01% | 71.18% | 66.86% | 73.04% | 72.57% | 73.34% | 73.25% | 70.80% | 68.13% | 62.79% | 65.60% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.50M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.43B | 233.50M | 173.80M | 133.50M | 158.50M | 166.80M | 115.70M | 83.61M | 64.24M | 45.02M | 740.00K | 560.00K |
| Selling & Marketing | 167.40M | 191.90M | 213.00M | 238.90M | 235.10M | 239.80M | 198.70M | 139.22M | 102.54M | 34.24M | 55.80M | 47.05M |
| SG&A | 1.60B | 425.40M | 386.80M | 372.40M | 393.60M | 406.60M | 314.40M | 222.83M | 166.78M | 79.26M | 56.54M | 47.61M |
| Other Expenses | 0.00 | 4.40M | 18.00M | 21.20M | 11.50M | 41.00M | 70.10M | 36.98M | 20.94M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.60B | 2.79B | 2.17B | 1.90B | 1.76B | 1.64B | 1.35B | 1.24B | 947.96M | 631.28M | 288.50M | 144.33M |
| Cost & Expenses | 4.74B | 4.42B | 3.87B | 3.53B | 2.93B | 2.75B | 2.30B | 2.05B | 1.65B | 1.21B | 847.49M | 606.15M |
| Interest Income | 26.90M | 13.80M | 7.10M | 7.90M | 7.00M | 6.60M | 5.00M | 2.04M | 280.00K | 3.40M | 34.14M | 42.28M |
| Interest Expense | 55.30M | 23.50M | 23.70M | 8.70M | 18.50M | 6.10M | 4.40M | 2.68M | 5.51M | 3.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 470.10M | 387.10M | 338.70M | 302.80M | 319.10M | 261.70M | 201.00M | 180.51M | 182.37M | 128.65M | 63.62M | 33.15M |
| EBITDA | 1.48B | 1.31B | 2.64B | 1.84B | 1.74B | 1.65B | 1.65B | 999.20M | 940.49M | 743.99M | 754.17M | 812.86M |
| EBITDA Ratio | 25.90% | 23.52% | 40.28% | 35.20% | 39.00% | 39.62% | 42.92% | 41.29% | 38.58% | 40.66% | 45.88% | 47.27% |
| Operating Income | 927.10M | 865.50M | 2.04B | 1.46B | 1.46B | 1.29B | 1.28B | 998.98M | 693.05M | 615.34M | 625.70M | 601.49M |
| Operating Income Ratio | 16.21% | 16.43% | 34.71% | 29.43% | 33.56% | 32.04% | 35.92% | 32.82% | 28.76% | 33.63% | 41.65% | 44.80% |
| Total Other Income/Expenses | 28.80M | 20.40M | 258.60M | 68.80M | -12.40M | 99.70M | 189.90M | -182.24M | 48.72M | 71.33M | 63.25M | 177.25M |
| Income Before Tax | 955.90M | 885.90M | 2.28B | 1.52B | 1.40B | 1.38B | 1.45B | 816.74M | 818.03M | 676.16M | 688.95M | 778.74M |
| Income Before Tax Ratio | 16.72% | 16.82% | 38.67% | 30.83% | 32.33% | 34.27% | 40.69% | 26.83% | 33.95% | 36.96% | 45.86% | 58.00% |
| Income Tax Expense | 264.90M | 242.30M | 515.80M | 393.20M | 520.10M | 529.20M | 517.10M | 388.29M | 300.03M | 235.78M | 227.39M | 210.55M |
| Net Income | 707.60M | 644.90M | 1.76B | 1.13B | 884.00M | 851.40M | 932.80M | 428.45M | 518.00M | 452.17M | 461.56M | 568.19M |
| Net Income Ratio | 12.37% | 12.24% | 29.91% | 22.88% | 20.36% | 21.13% | 26.18% | 14.08% | 21.50% | 24.71% | 30.72% | 42.32% |
| EPS | 13.42 | 12.16 | 33.30 | 21.41 | 16.74 | 15.95 | 17.36 | 8.00 | 10.06 | 9.14 | 10.57 | 13.01 |
| EPS Diluted | 13.34 | 12.14 | 33.24 | 21.37 | 16.70 | 15.91 | 17.32 | 7.98 | 10.06 | 9.14 | 10.57 | 13.01 |
| Weighted Avg Shares Out | 52.73M | 52.92M | 52.89M | 52.85M | 52.81M | 53.39M | 53.72M | 53.59M | 51.47M | 49.49M | 43.67M | 43.67M |
| Weighted Avg Shares Out (Dil) | 53.04M | 53.01M | 52.98M | 52.95M | 52.92M | 53.51M | 53.85M | 53.67M | 53.72M | 49.49M | 43.67M | 43.67M |
Source: https://incomestatements.info
Category: Stock Reports